The company continues to make progress across Ampligen® Clinical development program
Increasing encouraging data demonstrates Ampligen's potential to address multiple high-value indications
OCALA, Fla., February 29, 2024 (Globe Newswire) — AIM Immunotec Co., Ltd. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent achievements and provided an outlook for its business. AIM's dsRNA product candidate, Ampligen® (Rintatolimod) is being evaluated as a combination therapy for the treatment of various types of solid tumors in multiple ongoing and planned clinical trials at major cancer research centers across the country.
recent highlights
-
AMP-518 Clinical Study: Phase 2 Study Evaluating Ampligen as a Potential Treatment for People with Post-COVID-19 Fatigue
-
Strengthens Intellectual Property Rights with Significant U.S. Patent Issuance for Ampligen in Combination with Anti-PD-L1 Antibodies for Cancer Treatment
-
DURIPANC clinical trial: Phase 1b/2 clinical trial combining AIM's Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® For the treatment of pancreatic cancer (durvalumab)
“AIM's focus throughout 2024 will be to build on our strong foundation of scientific success,” said Thomas K. Equels, AIM's chief executive officer. “Our drug Ampligen is being evaluated in multiple indications, including pancreatic cancer, ovarian cancer, and the post-COVID-19 setting, and success in any of these areas will We believe this represents both a dramatic improvement in lives and significant value for our shareholders.”
Anticipated future milestones for Ampligen
Q1 2024
Q2 2024
2024
Continuous business development updates
As previously announced, the Company has acquired Azenova, a specialist business development (BD) consulting firm, to support efforts to partner with AIM's pipeline programs, with particular focus on the Company's flagship asset, Ampligen. LLC (“Azenova”).®, used in the treatment of various malignant solid tumors. Discussions regarding potential partnerships, licenses and other transactional activities are ongoing.
We continue to engage with the industry and investment community through ongoing clinical and business development activities, as well as active participation in meetings, virtual events, and major conferences throughout the year. To stay up to date on our activities, visit aimimmuno.com and connect with us on X, LinkedIn and Facebook.
About AIM Immunotec Co., Ltd.
AIM ImmunoTech Inc. is an immunopharmaceutical company focused on research and development of therapeutics to treat multiple types of cancer, immune disorders, and viral diseases, including coronavirus disease (COVID-19) .The company's flagship product is a first-in-class investigational drug called Ampligen.® (rintatolimod) is a dsRNA, highly selective TLR3 agonist immunomodulator that has demonstrated broad-spectrum activity in clinical trials in globally important cancers, viral diseases, and immune system disorders.
For more information, visit aimimmuno.com and connect with us on X, LinkedIn, and Facebook.
Notes
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “could,” and “future” , and other variations thereof and similar expressions (as well as other expressions or words or expressions that refer to future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. The Company advises investors of the various risk factors identified in its most recent Form 10-K and any risk factors or cautionary statements contained in any subsequent Form 10-Q or Form 8-K filed with the U.S. Securities and Exchange Commission. Encourage them to consider the matter in detail. (“SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, with respect to these statements, the Company claims safe harbor protection for forward-looking statements contained in the PSLRA. We undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date of this document.
CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
